SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act 1934

Date of Report: June 21, 2004

Titan Pharmaceuticals, Inc.
(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of incorporation)

0-27436	94-3171940
(Commission File Number)	(IRS Employer Identification No.)
400 Oyster Point Blvd., Suite 505, South San Francisco, CA	94080
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: 650-244-4990

Item 5. Other Events and Required FD Disclosure

On June 21, 2004, the registrant announced that an interim safety analysis by an independent data monitoring committee (IDMC) for its Phase IIb study of Pivanex in non-small cell lung cancer has identified significant safety issues in the combination treatment of Pivanex with docetaxel. As a result, the registrant has discontinued treatment with the combination regimen for the remaining patients on study. The registrant also plans to withhold further treatment and enrollment in the open data Phase IIa studies in CLL and melanoma until further analysis of the data from the Phase IIb study is available.

A copy of the press release dated June 21, 2004 is filed herewith as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

(c) Exhibits

Exhibit No.	Description
99.1	Press Release issued June 21, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Robert E. Farrell

Robert E. Farrell, Executive Vice President
and Chief Financial Officer

Dated: June 21, 2004

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release issued June 21, 2004.

Exhibit 99.1

Titan Pharmaceuticals, Inc.

Company:
Robert Farrell
Executive Vice President & CFO
650-244-4990

Media/Investors:
Jonathan Fassberg
The Trout Group
212-477-9077

FOR IMMEDIATE RELEASE

TITAN ANNOUNCES CHANGE IN PIVANEX® PHASE IIb STUDY FOLLOWING INTERIM SAFETY ANALYSIS

South San Francisco, CA - June 21, 2004 - Titan Pharmaceuticals, Inc. (ASE:TTP) announced today that an interim safety analysis by an independent data monitoring committee (IDMC) for its Phase IIb study of Pivanex in non-small cell lung cancer has identified significant safety issues in the combination treatment of Pivanex with docetaxel. As a result, Titan has discontinued treatment with the combination regimen for the remaining patients on study. Titan has not yet been provided with detailed data from the analysis performed by the IDMC. At present, the study will continue and Titan and the IDMC will review data available to determine any appropriate further steps.

There has been no evidence of significant toxicity in prior single agent Phase I and Phase II clinical studies, or in the prior dose ranging study of Pivanex in combination with docetaxel. Pivanex is an anti-cancer agent that inhibits histone deacetylases, a class of enzymes involved in cell growth.

"We are surprised by this result, since Pivanex has not been associated with any significant, dose limiting toxicity in previous studies that might explain these preliminary findings," stated Louis R. Bucalo, M.D., Chairman, President and CEO of Titan.

Titan also plans to withhold further treatment and enrollment in the open label Phase IIa studies in CLL and melanoma until further analysis of the data from the Phase IIb study is available.

About Titan Pharmaceuticals

TITAN PHARMACEUTICALS, INC. (ASE: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cancer and cardiovascular disease. Titan's numerous products in development utilize novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes partnerships with multinational pharmaceutical companies and government institutions for the development of its products.

The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.